Literature DB >> 10581487

Predictive testing of 25 percent at-risk individuals for Huntington disease (1987-1997).

A Maat-Kievit1, M Vegter-Van Der Vlis, M Zoeteweij, M Losekoot, A van Haeringen, R A Roos.   

Abstract

Before the mutation causing Huntington disease was identified, predictive testing of 25% at-risk persons with a 50% at-risk parent who did not wish to know his/her genetic status, was only possible by exclusion testing. The exclusion test, using linked markers, ensures the parent's wish not to know because the parent's risk is not changed. When mutation analysis became available in 1993, new testing options for 25% at-risk persons emerged: viz., the exclusion-definitive test and direct mutation analysis. These new tests not only disclose the risk of the test candidate, but may also change the risk of the at-risk parent and siblings. The testing options for 25% at-risk test applicants and their consequences are discussed and the testing procedures and results of testing 64 25% at-risk persons in the period 1987 to 1997 are described. Relatives received unsought information in 56% of the test procedures before and 34% after the mutation was identified. A decision tree and guidelines for predictive testing of 25% at-risk test applicants are proposed. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 88:662-668, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10581487     DOI: 10.1002/(sici)1096-8628(19991215)88:6<662::aid-ajmg16>3.0.co;2-a

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  6 in total

Review 1.  Ethical issues in neurogenetics.

Authors:  Wendy R Uhlmann; J Scott Roberts
Journal:  Handb Clin Neurol       Date:  2018

2.  Paradox of a better test for Huntington's disease.

Authors:  A Maat-Kievit; M Vegter-van der Vlis; M Zoeteweij; M Losekoot; A van Haeringen; R Roos
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-11       Impact factor: 10.154

Review 3.  A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases.

Authors:  Jane S Paulsen; Martha Nance; Ji-In Kim; Noelle E Carlozzi; Peter K Panegyres; Cheryl Erwin; Anita Goh; Elizabeth McCusker; Janet K Williams
Journal:  Prog Neurobiol       Date:  2013-09-11       Impact factor: 11.685

4.  Reverse pre-symptomatic testing for Huntington disease: double disclosure when 25% at-risk children reveal the genetic status to their parent.

Authors:  Adeline Bonnard; Ariane Herson; Marcela Gargiulo; Alexandra Durr
Journal:  Eur J Hum Genet       Date:  2018-09-11       Impact factor: 4.246

Review 5.  Huntington's disease: a clinical review.

Authors:  Raymund A C Roos
Journal:  Orphanet J Rare Dis       Date:  2010-12-20       Impact factor: 4.123

Review 6.  Huntington's Disease: A Clinical Review.

Authors:  Rajeshwar Andhale; Deepti Shrivastava
Journal:  Cureus       Date:  2022-08-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.